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Background: The aim of the study is to assess the efficacy of choline PET/CT regarding the detection of lymph
node (LN) metastases in recurrent prostate cancer (PCa).
Methods: 49 patients with a biochemical recurrence of PCa (PSA >0.2 ng/ml) were included in the study. All
patients were selected for further diagnostics with a choline-PET/CT. All patients underwent salvage extended
lymphadenectomy. The PET/CT result and the histological findings were analyzed regarding the specificity and
sensitivity and with respect to the localization of the metastases. The detection rate of LN metastases was analyzed
with respect to interdependencies between the pre-PET/CT PSA-value as well as the role of prior ADT.
Results: 41 out of 49 (83.6%) patients showed positive PET/CT results. Positive LNs were found in 27 out of 49
patients (55.1%). 48.9% of the PET-CT-findings proved true positive, 36.7% were found to be false positive. 8.1%
proved true negative and 8.1% false negative. This results in a specificity of 22.7% and a sensitivity of 85.1%. Out of
the true positive PET/CT scans, 61.9% were not congruent regarding the localization of positive LNs. In patients with
PSA [greater than or equal to] 5 ng/ml, the sensitivity of the PET/CT result was 93.7%, while specificity was 0%. In 24
patients who underwent ADT prior to the PET/CT diagnostics, the sensitivity was 84.6% and specificity 9.0%.
Conclusions: The reliability of PET/CT imaging for detection of LN metastases is limited by a high false-positive rate.
The influence of ADT further diminishes the PET/CT reliability. Sensitivity of the PET/CT is highest in patients with a
PSA of [greater than or equal to] 5 ng/ml. Based on our results, we propose the following conclusions: 1. There is
no well-established diagnostic alternative to Choline-PET/CT Scan. Therefore this method may continue to be
performed in patients with BCR. 2. It is not sufficient to remove only those LNs that show up in the PET/CT.
3. Salvage extended lymphadenectomy should follow a predefined template (e.g. the “Kiel template”) and not just
the PET/CT scan results.
Keywords: Prostate cancer recurrence; Detection of lymph node metastases; PET CT scanBackground
In case of a post-treatment biochemical recurrence of
prostate cancer (PCa), the diagnostic possibilities are cur-
rently limited to the distinction between a local recurrence
and a systemic manifestation. By the most common defin-
ition, a biochemical recurrence after radical prostatectomy
(RP) is present when the PSA-value reaches 0.2 ng/ml
after RP (EAU Guidelines 2010; Pound et al. 1999). After
radiation treatment (RT), a recurrence is present when the* Correspondence: dosmonov@urology.uni-kiel.de
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in any medium, provided the original work is pPSA is more than 2 ng/ml above the PSA nadir (EAU
Guidelines 2010; Horwitz et al. 2005).
The application of the tracer 18F-FDG ([18F]-2Fluor
2desoxyglucose) in PET/CT is successfully used in many
tumor types. However, a benefit in PCa diagnosis has
been pulled into question by several authors, including
Sanz et al. and Liu and co-workers (Sanz et al. 1999; Liu
et al. 2001). There have been divergent results on
Choline-PET/CT regarding PCa recurrence. The detec-
tion rates were analyzed and set in relation to the PSA
level in several studies. While it was found to be a useful
diagnostic method by Soyka and coworkers (Soyka et al.is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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visable when the PSA level is 1 ng/ml or higher accord-
ing to Picchio et al. (2011). Other studies have shown
the sensitivity of Choline-PET/CT to be as low as 41.1%
(Scattoni et al. 2007; Schiavina et al. 2008). In Table 1,
we have listed the results of different authors regarding
sensitivity and specificity.
This study sets out to determine whether or not the
method of PET/CT is suitable for accurate detection and
localization of lymph node (LN) metastases. The radio-
logical results are compared with the histological findings
to validate the specificity and sensitivity of the method. In
addition, our study aims to show whether or to which ex-
tent the rate of metastases detection may depend on the
PSA level at the time of PET/CT-investigation. A further
issue is the possible influence of androgen therapy on the
PET/CT detection rate. Furthermore, the reliability of
PET/CT in detecting skeletal metastases is compared with
the reliability of bone scintigraphy. The crucial question is
whether Choline-PET/CT should have an impact on the
treatment decision in PCa recurrence. We have tried to
formulate recommendations for clinical practice.Methods
This study is a retrospective analysis of case histories. The
patients suffered a relapse of PCa, which was treated at
our institution by salvage extended lymph node dissection
(sELND) according to the “Kiel Template” between 2004
and 2012 (Osmonov et al. 2014).
49 patients (n = 49) were included in the study. Pa-
tients 1 to 10 previously underwent RT. Patients 11 to
49 (n = 39) underwent primary RP. 32 of these RP
patients additionally underwent adjuvant RT. A bio-
chemical relapse was observed in all patients and a
Choline-PET/CT was performed in consequence. Those
patients with primary RT underwent salvage prostatec-
tomy (sRP) and sELND. The patients with primary RP
underwent only sELND. The mean age of the patients was
65 years (range 52–76) at the time of salvage surgery.
18F-choline was applied in 43 patients, 11-choline was
applied in 2 patients, 18FDG in one patient, and a
SPECT/CT scan was conducted in 3 patients.Table 1 Comparison of PET/CT reliability based on the
results from different authors
Sensitivity Specificity PPV NPV
(Farsad et al. 2005) 66.0% 81.0% 87.0% 55.0%
(Castellucci et al. 2011) 93.0% 74.0% 60.0% 96.0%
(Schiavina et al. 2008) 41.4% 99.8% 94.4% 97.2%
(Budiharto et al. 2011) 9.4% 99.7% 75.0% 91.0%
(Kjölhede et al. 2013) 33.0% 92.0% 76.0% 65.0%We also investigated the PET-CT true positive results
concerning the localization of the metastases by distin-
guishing only roughly between the left and right side of
the pelvis. Moreover, bone scintigraphy was performed
in 38 patients. Thus it was possible to compare the
current standard scintigraphy to the PET/CT result. The
total PSA (tPSA) prior to PET/CT and salvage operation




In 8 of 49 cases there was an inconspicuous PET/CT in
terms of LN metastases (16.3%). A positive PET/CT, in-
dicating the presence of LN metastases, was found in 41
of 49 patients (83.6%).
Histology
After removal of the pelvic LNs according to the “Kiel
template” the pathological analysis, the result regarding
the incidence of LN metastases was negative (pN0 sta-
tus) in 22 cases (44.9%). The mean PSA level in these
patients was 1.88 ng/ml. In 27 patients (55.1%), tumor
cells were detected in one or more LNs. The mean PSA
in these 27 patients was 8.76 ng/ml.
Comparison of PET/CT and histological results
Table 2 shows the data distribution. In 46.9% of all
cases the PET/CT was confirmed by the tissue exam-
ination and thus true-positive. In 36.7% of the cases,
the positive PET/CT finding was not confirmed by the
histological result, thus false-positive. In 8.2% of all
cases, the negative PET/CT result was confirmed by
histology and thus these were true false. In 8.2% of
the cases, the negative PET/CT scan result was proven
false-negative, as metastases were detected in the tis-
sue samples.
Specificity and sensitivity
There were 22 patients (44.9%) with a negative histology
result (pN0). Out of these, 4 patients were also had a
negative PET/CT result.
27 patients were found to have a positive histology re-
sult (55.1%). Out of these, 23 patients also had a positive






Positive PET/CT (41) 23/49 (46.9%) 18/49 (36.7%)
Negative PET/CT (8) 4/49 (8.2%) 4/49 (8.2%)
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– Specificity = true-negatives / (true-negatives + false-
positives)
– Sensitivity = true-positives / (true -positives + false-
negatives)
– Positive predictive value (PPV) = true-positives /
(true-positives + false-positives)
– Negative predictive value (NPV) = true-negatives /
(true-negatives + false-negatives)
Thus the following results were calculated:
– Specificity = 4 / (18 + 4) = 18.2%
– Sensitivity = 23 / (23 + 4) = 85.2%
– PPV = 23 / (23 + 18) = 56.1%
– NPV = 4 / (4 + 4) = 50.0%
Comparison of localization
For the true-positive results with a positive result both
in imaging and histology (23/49), it is crucial to deter-
mine whether there is also a match of the detected LN
metastasis localization. In the histology, 2 patients were
found to have the metastases on the left and 4 on the
right side of the pelvis, in 3 cases there were bilateral
metastases. However, only in 9 out of the 23 true-
positive cases (39.1%), the metastases were actually lo-
cated where the PET/CT showed them. Thus the rate of
true-positive results with correct localization was only 9
out of 49 (18.4%), with 32 false-positive results (65.3%),
and the aforesaid 4 true-negative and 4 false-negative re-
sults (8.2%).
Under additional consideration of the correct localiza-
tion, we calculated the following results regarding the
specificity and sensitivity of the PET/CT:
Specificity = 4 / (4 + 40) 9.1%
Sensitivity = 9 / (9 + 4) = 69.2%
PPV = 9 / (9 + 32) = 21.9%
NPV = 4 / (4 + 4) = 50.0%
Impact of the PSA value on the results
In the true-positive cases, the mean PSA level at the
time of PET/CT and salvage surgery was 9.43 ng/ml and
2.08 ng/ml in the false-positive cases. In the true-Table 3 Comparison of the PET/CT results at different PSA lev
PSA ≥5 ng/ml (n = 19) PSA ≥2- < 5 ng/ml (n
True-positive 15/19 (78.9%) 4/8 (50.0%)
False-positive 3/19 (15.8%) 2/8 (25.0%)
True-negative 0 0
False-negative 1/19 (5.3%) 2/8 (25.0%)
Specificity - -
Sensitivity 93.8% 66.7%negative cases, the PSA was 0.97 ng/ml and in false-
negative cases it was 3.34 ng/ml.
We analysed the results by matching them with differ-
ent PSA levels (≥5 ng/ml; ≥2- < 5 ng/ml; ≥1- < 2 ng/ml;
<1 ng/ml) and compared them with the overall specifi-
city (18.2%) and sensitivity (85.2%) as calculated for the
entire cohort (see also Table 3).
PSA ≥5 ng/ml (mean: 11.89 ng/ml), n = 19: the PET/
CT was true-negative in 0, true-positive in 15, false-
positive in 3 and false-negative in 1. Therefore, the sensi-
tivity is 93.8%.
PSA ≥2- < 5 ng/ml (mean: 3.49 ng/ml), n = 8: of these,
the PET/CT was true-negative in 0, true-positive in 4,
false-positive in 2 and false-negative in 2. Therefore, the
specificity is 0% and the sensitivity is 66.6%.
PSA ≥1- < 2 ng/ml (mean: 1.51 ng/ml), n = 12: of these,
the PET/CT was true-negative in 2, true-positive in 4,
false-positive in 6 and false-negative in 0. Therefore, the
specificity is 25% and the sensitivity is 100%.
PSA <1 ng/ml (mean: 0.68 ng/ml), n = 10: of these, the
PET/CT was true-negative in 2, true-positive in 0, false-
positive 7 and false-negative in 1 patient. Therefore, the
specificity is 22.2% and sensitivity 0%.Impact of ADT
A total of 24 out of 49 patients underwent ADT. We
compared the patients who were treated with ADT
(until maximum 4 weeks prior to PET/CT) with those
who were not. We registered only slight differences be-
tween the two groups (Table 4). However, the false-
negative results seem to be somewhat higher without
ADT. When comparing the specificity, it appears that
there is no difference (both 9.1%), while sensitivity is
slightly higher (84.6% and 78.0%) under ADT.Impact of the Gleason score
Poorly differentiated tumors with Gleason scores of 8–
10 are present in 21 of 49 cases. The specificity of PET/
CT metastases detection in this group is 22.2% and sen-
sitivity 83.3%. A preoperative Gleason-Score of 7 is
present in 18 patients with a specificity of 33.3% and
sensitivity of 83.3%. Gleason-Scores of 5–6 are present
in 6 cases, a sensitivity of 33.3% and a not calculableels
= 8) PSA ≥1- < 2 ng/ml (n = 12) PSA <1 ng/ml (n = 10)
4/12 (33.3%) 0
6/12 (50.0%) 7/10 (70.0%)




Table 4 Comparison of the PET/CT results of patients
with and without previous ADT
With hormonal
therapy (N = 24)
Without hormonal
therapy (N = 25)
True-positive 11/24 (45.8%) 11/25 (44.0%)
False-positive 10/24 (41.7%) 10/25 (40.0%)
True-negative 1/24 (4.2%) 1/25 (4.0%)
False-negative 2/24 (8.3%) 3/25 (12.0%)
Specificity (9.1%) (9.1%)
Sensitivity (84.6%) (78.6%)
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2–4, neither specificity nor sensitivity was calculable.
Correlation of PET/CT and bone scintigraphy
38 patients of the 49 patients additionally underwent a
bone scan. Of these, 8 scintigraphy images led to diagno-
sis of bone metastases (21.1%). In 2 of the 38 patients
the suspicion of bone metastases was based on the PET/
CT. A correlation of the bone scintigraphy and PET/CT
results is shown in Table 5. The PET/CT detection cap-
ability of bone metastases showed a specificity of 96.7%,
a sensitivity of 12.5%, a PPV of 50.0% and a NPV of
80.6%.
Discussion
At present, the EAU guidelines reject a recommendation
of the PET/CT due to the lack of evidence (EAU Guide-
lines 2010). Nevertheless, Scattoni et al. report high de-
tection rates, even for patients with low PSA-levels,
while conceding that the detection rate is limited at low
PSA-levels due to the non-discovery of microscopic
metastases (Giovacchini et al. 2012). Furthermore,
Schiavina and et al. argue that although a PET/CT sensi-
tivity of 60% is low in terms of LN metastases detection,
it is still higher than clinical nomograms. This study
group reports a specificity of 100% (Schiavina et al.
2008). A further study by Soyka et al. shows that the re-
sults of a PET/CT examination can lead to a change in
the treatment plan; thus the treatment strategy was
changed from curative to palliative and or from palliative
to curative due to the imaging results in 14% of the pa-
tients (Soyka et al. 2012).
On the other hand, Rybalov et al. argue that the accur-
acy of metastases detection is too small to justify the ap-






PET/CT positive (2) 1/2 (50.0%) 1/2 (50.0%)
PET/CT negative (36) 7/36 (19.4%) 29/36 (80.6%)test for patients with recurrent PCa (Rybalov et al. 2012).
Moreover, Salminen et al. point out that negative PET/CT
results should be judged carefully in particular (Salminen
et al. 2002). The DGU (Deutsche Gesellschaft für Urologie -
German Society of Urology) suggest that neither PET/CT
nor other imaging methods should be used as an alterna-
tive to biopsy (Wirth et al. 2009). Furthermore, Murphy
et al. have put forward that incorrect results might be re-
duced by training radiologists to distinguish more effect-
ively between a normal and pathological distribution of
PET tracers (Murphy et al. 2011). Budiharto et al. found
even lower results when analyzing the histology after
sELND (see Table 1) (Budiharto et al. 2011).
Ultimately, histological examination remains the gold
standard in the investigation of potentially malignant tis-
sue. Despite a negative PET/CT result, tumorous tissue
may already be present in the LNs, as metastases are
often too small to show up in the image.
In contrast to the current analysis, nearly all former
studies on PET/CT reliability for LN metastases detec-
tion were restricted to patients with positive PET-CT re-
sults. Moreover, subsequent lymphadenectomy is often
performed as limited PLND or semi-extended PLND. In
the current study we performed sELND according to the
“Kiel template” and the “Kiel salvage surgical principles”
(Osmonov et al. 2014). The “Kiel template” includes the
following anatomic regions: (1) para-aortal, (2) interilia-
cal, i.e. the area between the right and left common iliac
artery, (3) both sides of the common iliac artery, (4) the
region around the promontorium, (5) the presciatic area
resp. the “triangle Marcille”, (6) the region of the in-
ternal iliac artery, (7) the fossa obturatoria, (8) the region
of the external iliac artery, and (9) the sacral region
(Osmonov et al. 2014).
In the “Kiel salvage surgical principles”, we choose a
transperitoneal access and define landmarks such as the
iliac vessels before beginning with the dissection. The
ureter is identified and separated carefully from the sur-
rounding tissue. LN dissection is then performed sys-
tematically from top downwards. Small or medium clips
are used to avoid extensive ligation. Moreover, we use
the harmonic scalpel to seal the LN vessels and to
shorten the operation time (Osmonov et al. 2014).
Despite thorough dissection of all relevant lymph
nodes, we found a high percentage of patients with
false-positive PET/CT results (36.7%). Although 46.9%
of the patients were found to be true-positive for metas-
tases, it can be concluded that the PET/CT tends to
show a positive rather than a negative result, with a high
rate of false-positives.
Furthermore the high rate of false-negative results in
the PET/CT should also be considered carefully. In 4 out
of 8 PET/CT-negative patients, the result proved false-
negative, - in other words, these patients had histologically
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tients would have been declared as LN metastases-free, al-
though they were not, and thus they would have been
treated inadequately resp. undertreated if the treatment
decision had been made on the PET/CT alone.
Based on our data, we calculated a PET/CT specificity
of 18.2% and a sensitivity of 85.2%. A data distribution
with much higher sensitivity than specificity generally
shows an overestimation of positive results, i.e. the num-
ber of those patients who were mistakenly diagnosed
with LN metastases. The rate of patients, whose PET/
CT finding was confirmed by histology, was even lower.
The predictive values of the test were both very low
(PPV: 56.0% and NPV 50.0%).
When considering the lack of the PET/CT capacity to
show the correct localization of the lesions, the specifi-
city and sensitivity drop even further (9.1% and 69.2%).
In the current study, the only location criteria were left
or right side of the pelvis, therefore the accuracy of the
localization has been simplified. Despite this, there is no
match in terms of localization in 14 out of 23 (60.9%) of
the true-positive findings in the PET/CT. Consequently,
the localization of metastases in the PET/CT was actu-
ally confirmed by pathological examination in only 9 out
of all 49 patients (18.4%), or, in relation to all positive
PET/CT findings, 9 of 41 (21.9%). This proportion seems
too small to base the treatment decision on the PET/CT
alone. Even if surgical therapy was correctly chosen due
to the PET/CT, the ensuing surgery might be applied in
the wrong location.
Various publications show a lower detection capability
of the PET/CT in PCa recurrences with small PSA
values. Schillaci et al. recommend its use in patients with
PSA >2 ng/ml. According to their studies, the detection
rates are 20% at a PSA-value of 1 ng/ml, 55% at 1- ≤
2 ng/ml, 80% at 2- ≤ 4 ng/ml and 87% at >4 ng/ml
(Schillaci et al. 2012). These results are similar to the
findings of the current study. Graute et al. found that
the PET/CT has a relatively high detection capability
(specificity 74% and sensitivity 82%) above a PSA cut-off
value of 1.74 ng/ml (Graute et al. 2012).
Although it seems logical that patients with histologi-
cally proven LN metastases have a much higher mean
PSA compared to those with negative tissue samples
(8.76 ng/ml vs 1.88 ng/ml), our study did not clearly
confirm the dependence of true-positive PET/CT results
on the PSA level. The highest detection rates occurred
in the PSA range of ≥1- < 2 ng/ml, with a sensitivity of
100% but a specificity of only 25%. In summary, it can
be assumed that PET/CT imaging overestimates the per-
centage of LN metastases in patients with low PSA
values ≥1.
Moreover, we have also not been able to confirm a
clear impact of ADT prior to PET/CT, which is oftenput forward as a limiting factor in the literature. For ex-
ample, Fuccio et al. found that ADT preceding PET/CT
significantly decreases the detection capability due to a
lower choline uptake in tumorous cells when androgen
has been deprived (Fuccio et al. 2011). Based on our
current study, we conclude that hormonal treatment has
no effect on the PET/CT detection ability. Sensitivity and
specificity rates are comparable in fact, with a slightly
higher sensitivity in those patients with previous ADT.
When looking at the correlation with Gleason Score,
we found the highest specificity (33.3%) at GS 7 and a
relatively high sensitivity at 83.3% in patients with
Gleason Scores 7 and above. However, in the group GS
8–10, the PET/CT missed metastases in 2 out of 21 pa-
tients (11.1%). There was a true-positive result in 55.5%,
so the value is only somewhat higher than the overall
average (46.9%). Overall it seems that while Gleason
scores of or above 7 slightly increase the PET/CT’s sen-
sitivity, specificity remains low throughout.
In addition, we examined the capability of PET/CT re-
garding the detection of bone metastases. The gold
standard of bone scintigraphy, has sensitivity and specifi-
city rates of up to 100%, as reported by Even-Sapir
(Even-Sapir et al. 2006). In another study, Picchino et al.
found that in PET/CT the specificity (98–100%) was
higher, but the sensitivity (89%) was lower than in bone
scintigraphy; thus they conclude that PET/CT cannot re-
place bone scintigraphy, while claiming that a positive
result for bone metastases in the PET/CT is relatively
reliable (Picchio et al. 2012).
In our study, by contrast, we found a true-positive rate
of only 50.0% and a high false-negative rate (19.4%)
when comparing PET/CT with scintigraphy. Therefore,
we believe that PET/CT should not be used for distinct
diagnosis.
Conclusion
We found neither as clear influence of the Gleason-
Score nor of any specific PSA range on the reliability of
the PET/CT result, even though some authors claim that
the PSA value makes a big difference. While controver-
sial views persist, the actual impact remains uncertain at
this point. Furthermore, it was also not possible to verify
any influence of ADT on the accuracy of LN detection
with PET/CT imaging. Moreover, bone scintigraphy is
the gold standard and PET/CT cannot be given the same
relevance.
It is important to emphasize that it is risky to base a
treatment plan on the results of the PET/CT only as false-
positive and false negative findings may lead to inadequate
treatment, especially when including the inadequate
localization of LN metastases in the consideration.
Unfortunately, there is no reliable diagnostic method
for staging an advanced PCa respectively LN metastasis
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identify a more reliable imaging method for LN metasta-
ses detection, either by PET/CT with a more specific
tracer or by a completely different method.
To deal with the problem in the present situation we
propose adherence to “three Kiel principles” which are
based on our experience in PCa relapse salvage surgery:
1. There is no a well-established diagnostic alternative
to Choline-PET/CT Scan. Therefore this method
may still be performed in patients with BCR. But as
soon as a valid new diagnostic method becomes
available, it should be considered carefully as a
possible replacement of PET/CT.
2. It is not sufficient to remove only the LNs from the
regions with positive PET/CT imaging results. Our
analysis of sensitivity and specificity in relation to
the localization showed a low specificity value of
9.1% and a sensitivity of only 69.2%.
3. LN surgery should follow a predefined template (for
example the “Kiel template”) and not only the PET/
CT scan results (Pound et al. 1999) due to the risk
false negative results in the PET/CT.
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